Connection

Patrick Flume to Time Factors

This is a "connection" page, showing publications Patrick Flume has written about Time Factors.
Connection Strength

0.516
  1. Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742.
    View in: PubMed
    Score: 0.087
  2. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
    View in: PubMed
    Score: 0.073
  3. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9.
    View in: PubMed
    Score: 0.068
  4. Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros. 2015 Sep; 14(5):632-8.
    View in: PubMed
    Score: 0.067
  5. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 12 01; 204(11):1295-1305.
    View in: PubMed
    Score: 0.027
  6. Cystic fibrosis: when to consider lung transplantation? Chest. 1998 May; 113(5):1159-61.
    View in: PubMed
    Score: 0.021
  7. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials. 2018 01; 64:35-40.
    View in: PubMed
    Score: 0.020
  8. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790.
    View in: PubMed
    Score: 0.018
  9. Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2.
    View in: PubMed
    Score: 0.017
  10. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1.
    View in: PubMed
    Score: 0.017
  11. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
    View in: PubMed
    Score: 0.017
  12. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
    View in: PubMed
    Score: 0.016
  13. Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3.
    View in: PubMed
    Score: 0.015
  14. The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir Physiol. 1994 Jan; 95(1):53-66.
    View in: PubMed
    Score: 0.015
  15. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
    View in: PubMed
    Score: 0.013
  16. Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl. 2001 Dec; 7(12):1081-4.
    View in: PubMed
    Score: 0.007
  17. Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4.
    View in: PubMed
    Score: 0.006
  18. Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. Antimicrob Agents Chemother. 1997 Nov; 41(11):2527-32.
    View in: PubMed
    Score: 0.005
  19. The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.